Payment overview · 2025
General Payments
$311.71
12 reported records · 9 companies
Healthcare provider profile · identity verified
Nataly Bruk, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SARASOTA, FL · NPI 1689061707
Verified facts
What the public records show
CMS Open Payments records show Nataly Bruk, M.D received $311.71 in general payments during 2025 across 12 reported records.
Astellas Pharma US Inc accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Veozah by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $90.05 | 28.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.37 | 16.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.14 | 16.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.87 | 8.6% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $25.43 | 8.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.96 | 6.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.44 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.89 | 4.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.56 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.66 | 11 |
| Education | $90.05 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.37 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.14 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 445 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 75 |
| Losartan Potassium | Losartan Potassium | 262 | 77 |
| Lisinopril | Lisinopril | 216 | 61 |
| Alprazolam | Alprazolam | 180 | 50 |
| Metformin Hcl | Metformin Hcl | 161 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 46 |
| Omeprazole | Omeprazole | 141 | 41 |
| Gabapentin | Gabapentin | 139 | 41 |
| Alendronate Sodium | Alendronate Sodium | 121 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 38 |
| Sertraline Hcl | Sertraline Hcl | 115 | 31 |
| Simvastatin | Simvastatin | 113 | 35 |
| Celecoxib | Celecoxib | 101 | 28 |
| Prednisone | Prednisone | 96 | 81 |
| Trazodone Hcl | Trazodone Hcl | 93 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 36 |
| Eliquis | Apixaban | 82 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 21 |
| Famotidine | Famotidine | 78 | 23 |
| Meloxicam | Meloxicam | 78 | 33 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Ozempic | Semaglutide | 73 | suppressed |
| Valsartan | Valsartan | 72 | 22 |
| Bupropion Xl | Bupropion Hcl | 70 | 22 |
| Glimepiride | Glimepiride | 69 | 17 |
| Azithromycin | Azithromycin | 65 | 56 |
| Lorazepam | Lorazepam | 64 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 17 |
| Synthroid | Levothyroxine Sodium | 63 | 14 |
| Spironolactone | Spironolactone | 61 | 15 |
| Estradiol | Estradiol | 59 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 17 |
| Atenolol | Atenolol | 46 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 13 |
| Potassium Chloride | Potassium Chloride | 42 | 18 |
| Furosemide | Furosemide | 39 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 15 |
| Cephalexin | Cephalexin | 35 | 18 |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Methylprednisolone | Methylprednisolone | 34 | 28 |
| Propranolol Hcl | Propranolol Hcl | 34 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 20 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Carvedilol | Carvedilol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 11 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Diazepam | Diazepam | 29 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Tramadol Hcl | Tramadol Hcl | 23 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Finasteride | Finasteride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Levoxyl | Levothyroxine Sodium | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Veozah | Fezolinetant | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.71 · 12 records | Astellas Pharma US Inc | ABRYSVO, COMIRNATY, Kerendia, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOWST, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error